INOVA Diagnostics Revenue and Competitors
Estimated Revenue & Valuation
- INOVA Diagnostics's estimated annual revenue is currently $47.1M per year.
- INOVA Diagnostics's estimated revenue per employee is $155,000
Employee Data
- INOVA Diagnostics has 304 Employees.
- INOVA Diagnostics grew their employee count by -3% last year.
INOVA Diagnostics Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.7M | 61 | 9% | $53M | N/A |
#2 | $34.3M | 177 | 17% | $110M | N/A |
#3 | $0.4M | 273 | 5% | $236.7M | N/A |
#4 | $34.5M | 178 | -5% | $160M | N/A |
#5 | $3.7M | 24 | 20% | N/A | N/A |
#6 | $147.3M | 321 | 2% | $192.5M | N/A |
#7 | $17.5M | 113 | -3% | $24.1M | N/A |
#8 | $2.7M | 43 | 79% | N/A | N/A |
#9 | $34.1M | 220 | 100% | N/A | N/A |
#10 | $47.1M | 304 | -3% | N/A | N/A |
What Is INOVA Diagnostics?
INOVA Diagnostics, Inc. was formed in 1987 by a group of scientists—drawn from the academic, clinical and industrial communities but united by one common interest... Autoimmune Disease Diagnostic Technology! INOVA's founders include research scientists who were directly involved in the early development of autoimmune disease serology as well as the people responsible for the first commercially available
keywords:N/A
N/A
Total Funding
304
Number of Employees
$47.1M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
INOVA Diagnostics News
Antinuclear Antibody Testing Market Trends, Growth and Outlook 2022-2030| Key Players Bio-Rad Laboratories, Inc., Inova Diagnostics, Inc.
Siemens, Abbott, Thermo Fisher Scientific, Danaher, Bio-Rad Laboratories, GRIFOLS, Trinity Biotech, Inova Diagnostics, HYCOR Biomedical,...
Significant Key merchants/industry producers include: Inova Diagnostics; Bio-Rad; AIKANG; Agilent; DAS.srl; Oyster Bay Pump Works; Diatron.
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $102.6M | 304 | 24% | N/A |
#2 | $49.9M | 307 | 16% | N/A |
#3 | $105M | 311 | 4% | N/A |
#4 | $88.5M | 312 | N/A | N/A |
#5 | $46.3M | 314 | 21% | $340.5M |
